Discounted Cash Flow Rating

Sell

Return on Equity Rating

Strong Sell

Debt to Equity Rating

Strong Sell

Price to Earnings Rating

Neutral

Analyst Rating

Sell

Simple Moving Average

Sell

Exponential Moving Average

Sell

Relative Strength Index

Standard Deviation

Strong Buy

Williams %R

Strong Buy

Average Directional Index

Strong Sell

Insider Trading

Strong Buy

Wall Street Data Solutions Rating

Sell

C

CytomX Therapeutics, Inc. (CTMX)

Pharmaceutical Preparations

https://www.cytomx.com

CytomX Therapeutics Inc is an oncology-focused biopharmaceutical company which is operating in the United States. It is engaged in developing antibody therapeutics based on probody technology platform. The company probody technology platform to create proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.

151 OYSTER POINT BLVD., SUITE 400
SOUTH SAN FRANCISCO, CA

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

10/08/2015

Market Cap

91,389,780

Shares Outstanding

66,989,999

Weighted SO

66,988,904

Total Employees

N/A

Upcoming Earnings

08/13/2024

Similar Tickers

SPRO --.--%

NLTX --.--%

TIL --.--%

NXTC --.--%

ASMB --.--%

ACHL --.--%

NUVB --.--%

Beta

1.0590

Last Div

0.0000

Range

1.04-5.85

Chg

-0.0201

Avg Vol

1434650

Mkt Cap

91389780

Exch

NASDAQ

Country

US

Phone

650 515 3185

DCF Diff

2.1557

DCF

-0.0407

Div Yield

0.0000

P/S

0.7643

EV Multiple

8.3948

P/FV

-3.1800

Div Yield %

0.0000

P/E

8.9574

PEG

0.3237

Payout

0.0000

Current Ratio

1.0016

Quick Ratio

1.0016

Cash Ratio

0.3027

DSO

8.4711

DIO

0.0000

Op Cycle

8.4711

DPO

78.5817

CCC

-70.1107

Gross Margin

0.9763

Op Margin

0.0479

Pretax Margin

0.1261

Net Margin

0.0927

Eff Tax Rate

0.2648

ROA

0.0696

ROE

-0.2744

ROCE

0.3497

NI/EBT

0.7352

EBT/EBIT

2.6351

EBIT/Rev

0.0479

Debt Ratio

0.0738

D/E

-0.3761

LT Debt/Cap

-0.2828

Total Debt/Cap

-0.6029

Int Coverage

2.4432

CF/Debt

-7.3046

Equity Multi

-5.0988

Rec Turnover

43.0879

Pay Turnover

4.6448

Inv Turnover

0.0000

FA Turnover

8.8301

Asset Turnover

0.7510

OCF/Share

-1.0108

FCF/Share

-1.0166

Cash/Share

1.6162

OCF/Sales

-0.7176

FCF/OCF

1.0057

CF Coverage

-7.3046

ST Coverage

-17.6507

CapEx Coverage

-176.5432

Div&CapEx Cov

-176.5432

P/BV

-3.1800

P/B

-3.1800

P/S

0.7643

P/E

8.9574

P/FCF

-1.0591

P/OCF

-1.1574

P/CF

-1.1574

PEG

0.3237

P/S

0.7643

EV Multiple

8.3948

P/FV

-3.1800

DPS

0.0000

Latest Headlines (EST)

Zacks Investment Research Jan 22, 14:42 AstraZeneca's (AZN) Imfinzi Combo Meets Liver Cancer Study Goal Zacks Investment Research Jan 19, 13:09 TransCode (RNAZ) Down 50% on Issue of New Common Stock Zacks Investment Research Jan 15, 12:27 Iovance (IOVA) Surges More Than 150% in 3 Months: Here's Why Zacks Investment Research Jan 15, 12:27 Iovance (IOVA) Surges More Than 150% in 3 Months: Here's Why

Revenue Product Segmentation